SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-16-673647
Filing Date
2016-08-05
Accepted
2016-08-05 17:31:30
Documents
58
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d222301d10q.htm 10-Q 541005
2 EX-3.4 d222301dex34.htm EX-3.4 4146
3 EX-31.1 d222301dex311.htm EX-31.1 8871
4 EX-31.2 d222301dex312.htm EX-31.2 8877
5 EX-32.1 d222301dex321.htm EX-32.1 3482
6 EX-32.2 d222301dex322.htm EX-32.2 3493
  Complete submission text file 0001193125-16-673647.txt   3550064

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT kerx-20160630.xml EX-101.INS 616833
8 XBRL TAXONOMY EXTENSION SCHEMA kerx-20160630.xsd EX-101.SCH 37400
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kerx-20160630_cal.xml EX-101.CAL 57581
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kerx-20160630_def.xml EX-101.DEF 246494
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE kerx-20160630_lab.xml EX-101.LAB 343108
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kerx-20160630_pre.xml EX-101.PRE 288174
Mailing Address
Business Address 750 LEXINGTON AVENUE . NEW YORK NY 10022 212-531-5965
KERYX BIOPHARMACEUTICALS INC (Filer) CIK: 0001114220 (see all company filings)

IRS No.: 134087132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30929 | Film No.: 161812158
SIC: 2834 Pharmaceutical Preparations